Specific binding proteins and uses thereof

US7589180B2 · kind B2 · utility

Assignee

• Abbott Laboratories · US

Inventors

• Lloyd J. Old · New York, US
• Terrance Grant Johns · Melbourne, AU
• Con Panousis · Melbourne, AU
• Andrew Scott · Melbourne, AU
• Christoph Renner · Partenstein, DE
• Gerd Ritter · New York, US
• Achim Jungbluth · New York, US
• Elisabeth Stockert · New York, US
• Peter L. Collins · Kensington, US
• Webster K. Cavenee · Village of La Jolla, US
• Huei-Jen Su Huang · Rancho Santa Fe, US
• Antony Wilks Burgess · Melbourne, AU
• Edouard Collins Nice · Melbourne, AU

Key dates

• Filing date: May 13, 2002
• Grant date: Sep 15, 2009
• Expiry date: Jun 30, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/77
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.